Overview

A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)

Status:
Completed
Trial end date:
2018-07-28
Target enrollment:
Participant gender:
Summary
To evaluate the dose-response of different doses of CHF 1531 pressurized metered dose inhaler (pMDI) containing formoterol fumarate, on lung function and other clinical outcomes and to identify the optimal dose(s) with regard to benefit/ risk ratio for further development in the target subject population.
Phase:
Phase 2
Details
Lead Sponsor:
Chiesi Farmaceutici S.p.A.
Treatments:
Formoterol Fumarate